Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

LeanBio

- PMLiVE

Sandoz partners with Samsung Bioepis to develop up to five biosimilars

The agreement will expand the pipeline and builds on an existing partnership

- PMLiVE

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

- PMLiVE

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

- PMLiVE

Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

The initiative wants to increase the global use of biosimilars by at least 30% by 2030

- PMLiVE

Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

- PMLiVE

Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links